These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 33203511)

  • 1. Application of a High Throughput and Automated Workflow to Therapeutic Protein Formulation Development.
    Ren CD; Qi W; Wyatt EA; Yeary J; Westland K; Berke M; Rathore N
    J Pharm Sci; 2021 Mar; 110(3):1130-1141. PubMed ID: 33203511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational Characterization of Antibody-Excipient Interactions for Rational Excipient Selection Using the Site Identification by Ligand Competitive Saturation-Biologics Approach.
    Jo S; Xu A; Curtis JE; Somani S; MacKerell AD
    Mol Pharm; 2020 Nov; 17(11):4323-4333. PubMed ID: 32965126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis.
    He F; Woods CE; Trilisky E; Bower KM; Litowski JR; Kerwin BA; Becker GW; Narhi LO; Razinkov VI
    J Pharm Sci; 2011 Apr; 100(4):1330-40. PubMed ID: 24081468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of High Throughput Screening Techniques to Predict Stability of Monoclonal Antibody Formulations During Early Stage Development.
    Goldberg DS; Lewus RA; Esfandiary R; Farkas DC; Mody N; Day KJ; Mallik P; Tracka MB; Sealey SK; Samra HS
    J Pharm Sci; 2017 Aug; 106(8):1971-1977. PubMed ID: 28456733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering.
    Xu AY; Castellanos MM; Mattison K; Krueger S; Curtis JE
    Mol Pharm; 2019 Oct; 16(10):4319-4338. PubMed ID: 31487466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Product-Specific Impact of Viscosity Modulating Formulation Excipients During Ultra-High Concentration Biotherapeutics Drug Product Development.
    Rodrigues D; Tanenbaum LM; Thirumangalathu R; Somani S; Zhang K; Kumar V; Amin K; Thakkar SV
    J Pharm Sci; 2021 Mar; 110(3):1077-1082. PubMed ID: 33340533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-criteria manufacturability indices for ranking high-concentration monoclonal antibody formulations.
    Yang Y; Velayudhan A; Thornhill NF; Farid SS
    Biotechnol Bioeng; 2017 Sep; 114(9):2043-2056. PubMed ID: 28464235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies.
    Gibson TJ; Mccarty K; Mcfadyen IJ; Cash E; Dalmonte P; Hinds KD; Dinerman AA; Alvarez JC; Volkin DB
    J Pharm Sci; 2011 Mar; 100(3):1009-21. PubMed ID: 21280052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Near Infrared Spectroscopy as a PAT tool for monitoring and control of protein and excipient concentration in ultrafiltration of highly concentrated antibody formulations.
    Thakur G; Hebbi V; Rathore AS
    Int J Pharm; 2021 May; 600():120456. PubMed ID: 33711473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved Fluorescence Methods for High-Throughput Protein Formulation Screening.
    Wei Y; Larson NR; Angalakurthi SK; Russell Middaugh C
    SLAS Technol; 2018 Dec; 23(6):516-528. PubMed ID: 29884102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance analysis of high-throughput HPV testing on three automated workflows.
    Loonen AJM; Huijsmans CJJ; Geurts-Giele WRR; Leeijen C; van der Linden JC; van den Brule AJC
    APMIS; 2020 Aug; 128(8):497-505. PubMed ID: 32562292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities.
    Whitaker N; Xiong J; Pace SE; Kumar V; Middaugh CR; Joshi SB; Volkin DB
    J Pharm Sci; 2017 Nov; 106(11):3230-3241. PubMed ID: 28668340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development.
    Kamerzell TJ; Esfandiary R; Joshi SB; Middaugh CR; Volkin DB
    Adv Drug Deliv Rev; 2011 Oct; 63(13):1118-59. PubMed ID: 21855584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Excipient Effects on Reversible Self-Association, Backbone Flexibility, and Solution Properties of an IgG1 Monoclonal Antibody at High Concentrations: Part 1.
    Hu Y; Arora J; Joshi SB; Esfandiary R; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2020 Jan; 109(1):340-352. PubMed ID: 31201906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Small-Scale Process for Predicting Donnan and Volume Exclusion Effects During Ultrafiltration/Diafiltration Process Development.
    Abel J; Kosky A; Ball N; Bacon H; Kaushik R; Kleemann GR
    J Pharm Sci; 2018 May; 107(5):1296-1303. PubMed ID: 29339134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
    Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
    J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Excipient Extraction and Buffer Exchange on Recombinant Monoclonal Antibody Stability.
    Sarin D; Krishna K; Nejadnik MR; Suryanarayanan R; Rathore AS
    Mol Pharm; 2024 Apr; 21(4):1872-1883. PubMed ID: 38422397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated High-Throughput Permethylation for Glycosylation Analysis of Biologics Using MALDI-TOF-MS.
    Shubhakar A; Kozak RP; Reiding KR; Royle L; Spencer DI; Fernandes DL; Wuhrer M
    Anal Chem; 2016 Sep; 88(17):8562-9. PubMed ID: 27479043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theoretical analysis of excipient concentrations during the final ultrafiltration/diafiltration step of therapeutic antibody.
    Miao F; Velayudhan A; DiBella E; Shervin J; Felo M; Teeters M; Alred P
    Biotechnol Prog; 2009; 25(4):964-72. PubMed ID: 19569193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting diafiltration solution compositions for final ultrafiltration/diafiltration steps of monoclonal antibodies.
    Teeters M; Bezila D; Benner T; Alfonso P; Alred P
    Biotechnol Bioeng; 2011 Jun; 108(6):1338-46. PubMed ID: 21328314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.